Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification

Summary

This is a proof of concept, single-arm study to investigate crenolanib monotherapy in patients with recurrent/refractory glioblastoma with PDGFRA gene amplification by assessing the progression-free survival (PFS) at 6 months. Crenolanib will be given orally starting at 100 mg TID continuously until disease progression, unacceptable toxicity, or consent withdrawal.

Timeline

Start

2016-04

Primary completion

2020-07

Completion

2020-07

Drugs

Indications